Latest for Multiple Endocrine Neoplasia Type 1
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in… (J.M. de Laat)ClinicalTrials.gov
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Multiple Endocrine Neoplasia Type 1
The parathyroid glands are involved in >95% of patients, usually the first manifestation (typically by age 20-25), causing primary hyperparathyroidism with hypercalcemia (often 11-13mg/dL), nephrolithiasis (occurs in 20-40% from hypercalciuria), osteoporosis with increased fracture risk, and neuropsychiatric symptoms. Pancreatic/GI neuroendocrine tumors develop in approximately 70% of patients, including gastrin-secreting tumors causing Zollinger-Ellison syndrome (60-70% of pancreatic NETs), insulinomas, non-functional tumors, and pancreatic cancer risk.
Keep reading about Multiple Endocrine Neoplasia Type 1
Pituitary adenomas, particularly prolactin-secreting adenomas (60% of pituitary tumors), develop in 30-40% of patients causing hypogonadism and infertility. Adrenocortical tumors occur frequently (20-40% of patients) though typically nonfunctional. Thyroid adenomas, skin findings (facial angiofibromas, collagenomas, lipomas), carcinoid tumors, and other malignancies increase. Malignant potential varies significantly by tumor type; gastrinomas and pancreatic NETs demonstrate higher malignancy rates.
What are the symptoms of Multiple Endocrine Neoplasia Type 1?
These are common symptoms of Multiple Endocrine Neoplasia Type 1, and how strong they are varies from person to person.
- Primary hyperparathyroidism with hypercalcemia
- Gastroenteropancreatic neuroendocrine tumors
- Pituitary adenomas, often prolactin-secreting
- Nephrolithiasis from hypercalcemia
- Carcinoid syndrome from neuroendocrine tumors
- Bone loss and fracture risk
Who gets Multiple Endocrine Neoplasia Type 1?
Manifestations typically begin by age 20-40 years with hyperparathyroidism often first manifestation. Affects males and females equally with no gender predominance. Autosomal dominant inheritance with high penetrance (95%+ by age 50); offspring of affected parent have 50% risk of inheriting mutation.
Approximately 10% of cases represent new mutations without family history. Disease severity and tumor types vary considerably among affected individuals even within same family. Manifestations may be age-dependent with some tumors developing later in life. All populations affected equally; no ethnic or racial predisposition established.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Multiple Endocrine Neoplasia Type 1
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Multiple Endocrine Neoplasia Type 1 resources
Reputable organizations and medical references for learning more about Multiple Endocrine Neoplasia Type 1, including disease registries, foundation resources, and clinical guidelines.